A detailed history of Csenge Advisory Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Csenge Advisory Group holds 2,972 shares of VRTX stock, worth $1.38 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
2,972
Previous 3,402 12.64%
Holding current value
$1.38 Million
Previous $1.59 Million 13.3%
% of portfolio
0.07%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $197,800 - $217,485
-430 Reduced 12.64%
2,972 $1.38 Million
Q2 2024

Jul 10, 2024

BUY
$392.81 - $485.53 $250,612 - $309,768
638 Added 23.08%
3,402 $1.59 Million
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $105,184 - $115,088
258 Added 10.3%
2,764 $1.16 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $150,577 - $180,288
439 Added 21.24%
2,506 $1.02 Million
Q3 2023

Nov 01, 2023

BUY
$338.18 - $362.46 $38,552 - $41,320
114 Added 5.84%
2,067 $718,000
Q2 2023

Jul 20, 2023

BUY
$314.42 - $351.91 $70,115 - $78,475
223 Added 12.89%
1,953 $687,000
Q1 2023

May 01, 2023

BUY
$283.23 - $323.1 $96,864 - $110,500
342 Added 24.64%
1,730 $545,000
Q4 2022

Feb 10, 2023

BUY
$285.76 - $321.48 $50,865 - $57,223
178 Added 14.71%
1,388 $400,000
Q3 2022

Oct 04, 2022

BUY
$273.83 - $305.53 $331,334 - $369,691
1,210 New
1,210 $350,000
Q4 2018

Feb 07, 2019

SELL
$151.91 - $192.21 $7,747 - $9,802
-51 Closed
0 $0
Q3 2018

Nov 19, 2018

BUY
$167.73 - $192.74 $8,554 - $9,829
51 New
51 $8,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Csenge Advisory Group Portfolio

Follow Csenge Advisory Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Csenge Advisory Group with notifications on news.